SCHEMBL20424884

SCHEMBL20424884

CCCCCCC(=C\c1ccccc1)/C=C(\C)C(=O)OCC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.59
▸ LMNA P02545 6/20 0.57
▸ MEN1 O00255 6/20 0.54
▸ KMT2A Q03164 6/20 0.54
▸ MAPT P10636 5/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ S1PR4 O95977 1/20 0.44
▸ S1PR1 P21453 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ NR1H4 Q96RI1 1/20 0.43
▸ FAAH O00519 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ KDM4E B2RXH2 4/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ HPGD P15428 2/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20424885 1.00 TDP1 (0.59) TDP1LMNAMEN1KMT2AMAPT
SCHEMBL28893815 1.00 TDP1 (0.59) TDP1LMNAMEN1KMT2AMAPT
SCHEMBL24352321 0.99 LMNA (0.58) TDP1LMNAMEN1KMT2AMAPT
SCHEMBL24611349 0.90 MEN1 (0.59) TDP1LMNAMEN1KMT2AMAPT
SCHEMBL28893989 0.88 LMNA (0.54) TDP1LMNAMEN1KMT2AMAPT
SCHEMBL24352194 0.88 TDP1 (0.44) TDP1LMNAMEN1KMT2AMAPT
SCHEMBL28893988 0.88 LMNA (0.54) TDP1LMNAMEN1KMT2AMAPT
SCHEMBL20441171 0.87 MEN1 (0.50) TDP1LMNAMEN1KMT2AMAPT
SCHEMBL24611339 0.86 TDP1 (0.42) TDP1LMNAMEN1KMT2AMAPT
SCHEMBL20424327 0.85 TDP1 (0.71) TDP1LMNAMEN1KMT2ACES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115710181-A Compounds for reducing perception of malodour and uses thereof 凯姆克姆公司 2023-02-24 — — CN disclosed
JP-2023025081-A COMPOUNDS FOR REDUCING MALODOUR PERCEPTION AND THE USE THEREOF ケムコム エス アー 2023-02-21 — — JP disclosed
US-20220378675-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM S.A. (BE) 2022-12-01 — — US disclosed
CN-110494413-B Compounds for reducing perception of malodour and uses thereof 凯姆克姆公司 2022-11-22 — — CN disclosed
EP-4059917-A2 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF ChemCom S.A. (BE) 2022-09-21 — — EP disclosed
US-11382848-B2 Compounds reducing malodour perception and the use thereof CHEMCOM S.A. (BE) 2022-07-12 — — US disclosed
US-11382848-B2 Compounds reducing malodour perception and the use thereof CHEMCOM S.A. (BE) 2022-07-12 — — US disclosed
EP-3573944-B1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM SA (BE) 2022-03-02 — — EP disclosed
EP-3573944-B1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM SA (BE) 2022-03-02 — — EP disclosed
WO-2018138369-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM S.A. (BE) 2018-08-02 — — WO disclosed
WO-2018138369-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF CHEMCOM S.A. (BE) 2018-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11382848-B2 Compounds reducing malodour perception and the use thereof OR51E2, OR10J3, SRD5A1 TDP1 4689/4885LMNA 4749/4885MEN1 1364/4885
US-20220378675-A1 COMPOUNDS REDUCING MALODOUR PERCEPTION AND THE USE THEREOF OR51E2, OR10J3, SRD5A1 TDP1 4689/4885LMNA 4749/4885MEN1 1364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback